Membrane fas ligand kills human peripheral blood T lymphocytes, and soluble fas ligand blocks the killing

被引:428
作者
Suda, T
Hashimoto, H
Tanaka, M
Ochi, T
Nagata, S
机构
[1] Osaka Biosci Inst, Dept Mol Biol, Suita, Osaka 565, Japan
[2] Osaka Univ, Sch Med, Dept Orthopaed Surg, Suita, Osaka 565, Japan
[3] Osaka Univ, Sch Med, Dept Genet, Suita, Osaka 565, Japan
关键词
D O I
10.1084/jem.186.12.2045
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
It has been believed that die Fas expressed on human peripheral blood T cells (PBT) is nonfunctional, because these cells are insensitive to agonistic anti-Fas/Apo-2 mAbs that efficiently kill in vitro-activated T cells and many Fas-expressing cell lines. Here, we demonstrate that membrane-bound Fas ligand (FasL) kills both fresh and in vitro-activated PET, indicating that the Fas expressed on fresh PBT is functional. In contrast, soluble Fast kills only the latter. Naive T cells in umbilical cord blood do not express Fas, but can be induced to express Fas by IFN-gamma or by a combination of IL-2 and anti-CD28 mAb, after which they acquire sensitivity to membrane but not to soluble FasL. Soluble FasL inhibited the killing of flesh PBT by membrane FasL. These results indicate that the shedding of FasL from the membrane is a mechanism for downregulating at least part of its killing activity.
引用
收藏
页码:2045 / 2050
页数:6
相关论文
共 30 条
[1]   MECHANISMS OF CLASS-I RESTRICTED IMMUNOPATHOLOGY - A TRANSGENIC MOUSE MODEL OF FULMINANT-HEPATITIS [J].
ANDO, K ;
MORIYAMA, T ;
GUIDOTTI, LG ;
WIRTH, S ;
SCHREIBER, RD ;
SCHLICHT, HJ ;
HUANG, SN ;
CHISARI, FV .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (05) :1541-1554
[2]   A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION [J].
BELLGRAU, D ;
GOLD, D ;
SELAWRY, H ;
MOORE, J ;
FRANZUSOFF, A ;
DUKE, RC .
NATURE, 1995, 377 (6550) :630-632
[3]   A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells [J].
Black, RA ;
Rauch, CT ;
Kozlosky, CJ ;
Peschon, JJ ;
Slack, JL ;
Wolfson, MF ;
Castner, BJ ;
Stocking, KL ;
Reddy, P ;
Srinivasan, S ;
Nelson, N ;
Boiani, N ;
Schooley, KA ;
Gerhart, M ;
Davis, R ;
Fitzner, JN ;
Johnson, RS ;
Paxton, RJ ;
March, CJ ;
Cerretti, DP .
NATURE, 1997, 385 (6618) :729-733
[4]   Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease [J].
Braun, MY ;
Lowin, B ;
French, L ;
AchaOrbea, H ;
Tschopp, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (02) :657-661
[5]   Anti-Fas IgG1 antibodies recognizing the same epitope of Fas/APO-1 mediate different biological effects in vitro [J].
Fadeel, B ;
Thorpe, CJ ;
Yonehara, S ;
Chiodi, F .
INTERNATIONAL IMMUNOLOGY, 1997, 9 (02) :201-209
[6]   Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-I fax transgenic mice [J].
Fujisawa, K ;
Asahara, H ;
Okamoto, K ;
Aono, H ;
Hasunuma, T ;
Kobata, T ;
Iwakura, Y ;
Yonehara, S ;
Sumida, T ;
Nishioka, K .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (02) :271-278
[7]   Potential involvement of fas and its ligand in the pathogenesis of Hashimoto's thyroiditis [J].
Giordano, C ;
Stassi, G ;
DeMaria, R ;
Todaro, M ;
Richiusa, P ;
Papoff, G ;
Ruberti, G ;
Bagnasco, M ;
Testi, R ;
Galluzzo, A .
SCIENCE, 1997, 275 (5302) :960-963
[8]   THE TRANSMEMBRANE FORM OF TUMOR-NECROSIS-FACTOR IS THE PRIME ACTIVATING LIGAND OF THE 80 KDA TUMOR-NECROSIS-FACTOR RECEPTOR [J].
GRELL, M ;
DOUNI, E ;
WAJANT, H ;
LOHDEN, M ;
CLAUSS, M ;
MAXEINER, B ;
GEORGOPOULOS, S ;
LESSLAUER, W ;
KOLLIAS, G ;
PFIZENMAIER, K ;
SCHEURICH, P .
CELL, 1995, 83 (05) :793-802
[9]   FAS LIGAND-INDUCED APOPTOSIS AS A MECHANISM OF IMMUNE PRIVILEGE [J].
GRIFFITH, TS ;
BRUNNER, T ;
FLETCHER, SM ;
GREEN, DR ;
FERGUSON, TA .
SCIENCE, 1995, 270 (5239) :1189-1192
[10]   METALLOPROTEINASE-MEDIATED RELEASE OF HUMAN FAS LIGAND [J].
KAYAGAKI, N ;
KAWASAKI, A ;
EBATA, T ;
OHMOTO, H ;
IKEDA, S ;
INOUE, S ;
YOSHINO, K ;
OKUMURA, K ;
YAGITA, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (06) :1777-1783